electroCore Overview
- Founded
-
2005
- Status
-
Public
- Employees
-
62
- Stock Symbol
-
ECOR
- Share Price
-
$5.34
- (As of Friday Closing)
electroCore General Information
Description
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients and the prevention of migraine in adult patients. The gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache, Bronchoconstriction and Medication Overuse Headache in adults.
Contact Information
Website
www.electrocore.com
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Devices and Supplies
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 150 Allen Road
- Suite 201
- Basking Ridge, NJ 07920
- United States
+1 (888) 000-0000
electroCore Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.34 | $4.28 | $2.92 - $10.50 | $20.3M | 4.74M | 24.5K | -$4.69 |
electroCore Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (2,655) | (2,655) | 3,915 | 49,192 |
| Revenue | 8,592 | 8,592 | 5,451 | 3,496 |
| EBITDA | (22,332) | (22,332) | (17,698) | (24,367) |
| Net Income | (22,162) | (22,162) | (17,218) | (23,511) |
| Total Assets | 24,756 | 24,756 | 42,833 | 31,518 |
| Total Debt | 699 | 699 | 761 | 2,829 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
electroCore Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
electroCore Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimul
Other Devices and Supplies
Basking Ridge, NJ
62
As of 2022
00000
00000000
00000
000000
e velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cup
00000000000 0000000
Irvine, CA
000
As of 0000
00000
000000 - 000
00000
00000
pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui off
00000000000 0000000
Irvine, CA
000
As of 0000
000.00
000000000
000.00
Add Comparison
electroCore Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Axonics | Formerly VC-backed | Irvine, CA | 000 | 00000 | 000000 - 000 | 00000 |
| 00000 0000000 0000 | Private Equity-Backed | Irvine, CA | 000 | 000.00 | 000000000 | 000.00 |
| 000000 (0000000000 | Venture Capital-Backed | Pleasanton, CA | 00 | 00000 | 00000000000 | 00000 |
| 000000 | Venture Capital-Backed | Trumbull, CT | 00 | 000.00 | 0000000000 | 000.00 |
| 000000 0000000 | Venture Capital-Backed | Artarmon, Australia | 000 | 00000 | 00000000000 | 00000 |
electroCore Patents
electroCore Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200230408-A1 | Systems and methods for treating patients with diseases associated with replicating pathogens | Pending | 21-Dec-2018 | 00000000000 | |
| US-20220044828-A1 | Systems and methods for treating patients with diseases associated with viruses | Pending | 22-Dec-2017 | 000000000 | 0 |
| EP-3703813-A1 | Systems and methods for initial provisioning and refilling of medical devices | Pending | 22-Dec-2017 | 000000000 | |
| EP-3703813-A4 | Systems and methods for initial provisioning and refilling of medical devices | Pending | 22-Dec-2017 | 000000000 | 0 |
| US-20200398054-A1 | Systems and methods for initial provisioning and refilling of medical devices | Pending | 22-Dec-2017 | G16H20/30 | 0 |
electroCore Executive Team (22)
electroCore Board Members (19)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 000 | Self | Board Member | 000 0000 |
| 000000 0000000000 | electroCore | Chief Executive Officer & Board Member | 000 0000 |
| 0000000 00000 | electroCore | Chief Executive Officer & Board Member | 000 0000 |
| 0000 00000000 | Self | Board Member | 000 0000 |
| 0.0. 000000 00 | electroCore | Co-Founder & Board Member | 000 0000 |
electroCore Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
electroCore Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
electroCore ESG
Risk Overview
Risk Rating
Updated July, 18, 2020
42.71 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 13,035
Rank
00.00
Percentile
Healthcare
Industry
00 of 521
Rank
00.00
Percentile
Medical Devices
Subindustry
00 of 163
Rank
00.00
Percentile
